# Phase 2 Neoplasm, Residual trials recruiting: 36 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials in phase 2 for Neoplasm, Residual that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Neoplasm, Residual trials: 36 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/neoplasm-residual

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 36
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07901868 | Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | PETHEMA Foundation | Phase 2 | Not yet recruiting | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901868) |
| October 23, 2026 | NCT07891923 | Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma | Tata Memorial Centre | Phase 2 | Recruiting | Newly Diagnosed Multiple Myeloma (NDMM) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891923) |
| October 21, 2026 | NCT07885709 | MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC | Peking University People's Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer (NSCLC) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885709) |
| October 2, 2026 | NCT07856303 | SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response | Fudan University | Phase 2 | Not yet recruiting | HER2-positive Breast Cancer, Early Breast Cancer (EBC) | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856303) |
| September 25, 2026 | NCT07841236 | ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer | Fudan University | Phase 2 | Recruiting | Colon Cancer, Deficient Mismatch Repair, Microsatellite Instability-High (MSI-H) | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841236) |
| September 21, 2026 | NCT07830485 | CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830485) |
| September 16, 2026 | NCT07823322 | A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After... | Incyte Corporation | Phase 2 | Recruiting | CRC (Colorectal Cancer) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823322) |
| September 10, 2026 | NCT07811375 | Perioperative Adebrelimab for Locally Advanced Cervical Cancer | Anhui Provincial Hospital | Phase 2 | Not yet recruiting | Locally Advanced Cervical Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811375) |
| August 6, 2026 | NCT07748689 | Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple... | Polish Myeloma Consortium | Phase 2 | Not yet recruiting | Relapsed / Refractory Multiple Myeloma | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748689) |
| July 16, 2026 | NCT07709585 | Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated... | Guangzhou University of Traditional Chinese Medicine | Phase 2 | Recruiting | Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation, EGFR Exon 21 Mutation, EGFR Exon 21 L858R... | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709585) |
| July 8, 2026 | NCT07690891 | Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690891) |
| May 7, 2026 | NCT07572929 | A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572929) |
| April 8, 2026 | NCT07517705 | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma | University of Nebraska | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517705) |
| April 2, 2026 | NCT07507318 | Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission | Sponsor not shown (see the record) | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507318) |
| February 6, 2026 | NCT07392970 | Motixafortide for MRD Sensitization in AML | Washington University School of Medicine | Phase 2 | Recruiting | Acute Myeloid Leukemia, Measurable Residual Disease | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392970) |
| December 24, 2025 | NCT07301138 | BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients | Ruijin Hospital | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301138) |
| December 2, 2025 | NCT07257380 | Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With... | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Gastric / Gastroesophageal Junction Adenocarcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07257380) |
| July 16, 2025 | NCT07069595 | PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07069595) |
| June 15, 2025 | NCT07021677 | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" | Tata Memorial Centre | Phase 2 | Recruiting | T Acute Lymphoblastic Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07021677) |
| May 29, 2025 | NCT06993675 | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Multiple Myeloma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06993675) |
| April 30, 2025 | NCT06951646 | ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy... | Second Xiangya Hospital of Central South University | Phase 2 | Recruiting | Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06951646) |
| March 20, 2025 | NCT06886074 | Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Measurable Residual Disease (MRD) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06886074) |
| February 17, 2025 | NCT06828991 | A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06828991) |
| December 5, 2024 | NCT06718244 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 | Ruijin Hospital | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06718244) |
| September 23, 2024 | NCT06608732 | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With... | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06608732) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Ruijin Hospital | 2 |
| Tata Memorial Centre | 2 |
| Medical College of Wisconsin | 2 |
| Fudan University | 2 |
| PETHEMA Foundation | 1 |
| Beijing 302 Hospital | 1 |
| Washington University School of Medicine | 1 |
| University of Alabama at Birmingham | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| Anhui Provincial Hospital | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Stanford University | 1 |
| Allogene Therapeutics | 1 |
| Second Xiangya Hospital of Central South University | 1 |
| Gruppo Oncologico del Nord-Ovest | 1 |
| Hospital Universitario Dr. Jose E. Gonzalez | 1 |
| University of Southampton | 1 |
| University of Nebraska | 1 |
| Technische Universität Dresden | 1 |
| Peking University People's Hospital | 1 |
| Peter MacCallum Cancer Centre, Australia | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Polish Myeloma Consortium | 1 |
| Guangzhou University of Traditional Chinese Medicine | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 14 |
| United States | 13 |
| India | 2 |
| Australia | 2 |
| Spain | 1 |
| Puerto Rico | 1 |
| Canada | 1 |
| South Korea | 1 |
| Italy | 1 |
| Mexico | 1 |
| United Kingdom | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Merchandising companies in the United States](https://specstream.ai/data/businesses/merchandising-companies/united-states)
- [Pulmonology practices in the United States](https://specstream.ai/data/businesses/pulmonology-practices/united-states)
- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
- [Crane services in the United States](https://specstream.ai/data/businesses/crane-services/united-states)
- [Generator installation repair companies in the United States](https://specstream.ai/data/businesses/generator-installation-repair-companies/united-states)
